AI Summary

Hepatocellular Carcinoma: Controversies in Management

Comprehensive Structured Summary

1. Main Clinical Topics Discussed

Surveillance strategies for HCC in various patient populations (cirrhotic, NASH, post-SVR, HBV carriers)
Diagnostic modalities and biomarkers for HCC detection
Staging systems (BCLC, TNM, LI-RADS)
Multidisciplinary management including resection, transplantation, locoregional therapy, and systemic treatment
Cost-effectiveness considerations in surveillance and treatment decisions

2. Key Learning Points, Guidelines, and Recommendations

Surveillance Indications

Threshold for cost-effective surveillance: ≥3 months gain in lifespan OR HCC incidence >1.5%/year
Standard indications: All patients with cirrhosis (any etiology), including HBV, HCV, PBC, hemochromatosis, alpha-1 antitrypsin deficiency
Special HBV exceptions (surveillance recommended even without cirrhosis):

- Asian males >40 years

- Asian females >50 years

- HBV carriers with family history of HCC

- African Americans with HBV at any age

Uncertain/controversial indications: Post-SVR HCV with advanced fibrosis (non-cirrhotic), NASH without cirrhosis — incidence <1.5%/year; updated cost-effectiveness models needed

Surveillance Protocol (Current Guidelines)

Modality: Ultrasound ± AFP every 6 months
If negative: Continue every 6 months
If positive (lesion ≥1 cm or AFP >20): Proceed to multiphasic CT or MRI
If indeterminate: Repeat ultrasound ± AFP in 3–6 months
Critical gap: <20% of cirrhotic patients currently undergo recommended surveillance

LI-RADS Diagnostic Criteria

LI-RADS 5 (definite HCC):

- Lesion ≥2 cm: Arterial phase hyperenhancement + one of: non-peripheral washout, enhancing capsule, or threshold growth (>50% increase in <6 months)

- Lesion 10–19 mm: Requires arterial enhancement AND all three: washout + capsule + threshold growth

LI-RADS 4, 5, or M: May require biopsy
LI-RADS 1: Repeat imaging in 6 months
LI-RADS 2–3: Repeat in 3 months

BCLC Staging and Treatment Allocation

Stage	Criteria	Treatment
0	Single <2 cm, Child-Pugh A	Resection or ablation (RFA/MWA)
A	Single ≤5 cm or 2–3 nodules ≤3 cm, good functional status	Transplant preferred; resection or ablation
B (intermediate)	>5 cm or multinodular, no vascular invasion	Locoregional therapy (TACE/TARE); consider downstaging to transplant
C	Vascular invasion or metastasis	Systemic therapy ± TARE
D	Child-Pugh C or severe decompensation	Transplant or best supportive care

Transplant Criteria

Milan Criteria (standard): Single tumor ≤5 cm OR 2–3 tumors ≤3 cm each; no vascular invasion or extrahepatic spread
UCSF/Expanded Criteria: Single tumor ≤6.5 cm OR 2–3 lesions none >4.5 cm, total diameter ≤8 cm; no vascular invasion

Resection Considerations

Preferred for localized HCC without cirrhosis, or in cirrhosis with intact liver function and no clinically significant portal hypertension
Tumor size/number not absolute contraindications in many international guidelines (Asia-Pacific)
High-risk resection: Portal hypertension + >3 segment involvement → >30% risk of decompensation

This summary was generated by AI and may contain inaccuracies. Always refer to the original lecture and consult clinical guidelines for medical decision-making.

Hepatocellular Carcinoma: Controversies in the Management